X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to unravel novel biological drivers of MASH and will leverage Cellarity’s platform to develop a small molecule therapy against this disease.
Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $532.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2024
Details:
The proceeds of the financing will be used to grow Cellarity’s talent base, strengthen its platform, and advance its pipeline toward the clinic with the development of compounds that have been validated in vitro and in vivo, including in higher species.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Flagship Pioneering
Deal Size: $274.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing October 04, 2022
Details:
Cellarity’s new approach to drug discovery is based on the computational modeling of cell behavior, leading to a more complete understanding of system and network biology to uncover cell-behavior-targeted medicines for a wide variety of diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: BlackRock
Deal Size: $123.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 25, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
